Highest-materiality recent filing
Tarsus Q1 XDEMVY sales $145.4M (+85% YoY); net loss narrows to $7.0M
XDEMVY net product sales $145.4M vs $78.3M YoY; gross margin 94%.
Q4 2025 net product sales $151.7M (Q4 2024: $66.4M); full-year $451.4M; ~400,000 bottles delivered in 2025.
Tarsus appoints former Allergan CEO David Pyott to Board of Directors
Pyott appointed as Class III director effective Feb 18, 2026; term expires at 2026 annual meeting.
Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share
XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.
Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M
Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.
Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M
Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.
Tarsus closes public offering of 3.23M shares; net proceeds $134.8M
Underwriters exercised full over-allotment; total shares sold: 3,230,336 (incl. 421,348 additional shares).
Tarsus prices upsized $125M public offering of 2.8M shares at $44.50/share
Offering of 2,808,988 shares at public price $44.50; net proceeds ~$117.1M.
Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share
Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.
Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M
Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.
Tarsus appoints Elizabeth Yeu as CMO; she resigns from board
Dr. Yeu appointed Chief Medical Officer effective Nov 4, 2024; resigned from Board same date.
Tarsus Q2 2024: XDEMVY net sales $40.8M (65% QoQ), net loss $33.3M, gross-to-net improves to 44%
XDEMVY net product sales $40.8M in Q2, up 65% over Q1; year-to-date $65.5M.
Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M
Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).
Tarsus secures $200M non-dilutive credit facility from Pharmakon; draws $75M initially
Initial $75M drawn April 19, 2024; used to repay Hercules Capital/SVB debt and for corporate purposes.
Tarsus Pharmaceuticals completes public offering, raising net proceeds of $107.8M
Sold 3,281,250 shares and pre-funded warrants for 312,500 shares at $32.00 public price.
Tarsus prices $100M public offering of common stock and pre-funded warrants at $32/share
Offering consists of 2,812,500 shares common stock at $32.00/share and pre-funded warrants for 312,500 shares at $31.9999 each.
Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data
XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.
On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025.
On November 5, 2024, Tarsus Pharmaceuticals, Inc. (the "Company") announced the appointment of Elizabeth Yeu, M.D. as the Company's Chief Medical Officer, effective as of November 4, 2024 (the "Effective Date").
In connection with the appointment, on November 1, 2024, Dr. Yeu resigned as a member of the Company's board of directors (the "Board") and from the committees of the Board on which she served, each effective as of the Effective Date.
Max materiality 0.85 · Median 0.70 · Most common event earnings